Trident Lifeline Ltd. · BSE:TLL
Trident Lifeline — Q4 FY23 Earnings Presentation
30 slides from Trident Lifeline's earnings presentation, May 6, 2023
Slide 1: BSE Regulation 30 Earnings Presentation Cover Letter
CINNo.:L51909GJ2014PLC078227 ~Trl.lOENT™ GST No. : 24AAECT8906D1ZG ~ LIFELINE TRIDENT LIFELINE LIMITED (Formerly Trident Lifeline Private Limited) Date: 06th May, 2023 BSE Limited Stock ID: TLL 14th Floor, P. J, Towers, Scrip Code: 543616 Dalal Street, Fort, Mumbai - 400001. Dear Sir/Ma'am, Sub: Ear
Slide 2: Q4 & FY23 Presentation
Q4 & FY23 Presentation Tr i d e n t L i f e l i n e L i m i t e d May 2023
Slide 3: Inside the document
Inside the document Pg. 03 __ Company Over view Pg. 09 __ Expansive Product Portfolio Pg. 13 __ Global Footprint Pg. 17 __ Leadership Pg. 18 __ Strategy & Investment Rationale Pg. 23 __ Financials & Management Commentar y
Slide 4: Company Overview
| i 9 Company || Overview
Slide 5: Trident Texofab Group
Trident Texofab Group Part of the Trident Texofab Group (“the Group”) with interests in textiles, pharmaceuticals and medical equipments. Trident Texofab Trident Lifeline Trident Mediquip Limited Limited Limited Trident Texofab Limited, a semi-composite Trident Lifeline Limited is a diversified Trid
Slide 6: Introduction to Trident Lifeline
Introduction to Trident Lifeline About us A growing force in pharmaceutical Trident Lifeline Limited (“Trident formulations export. Vision Lifeline” or “the Company”) 411 1067 25 To be a leading is a diversified pharmaceutical pharmaceutical company Company with business globally by providing high-
Slide 7: Superior Business Model
Superior Business Model A growing force in 411 1067 25 pharmaceutical Export market Export market product Countries present formulations products registered registrations in process in globally export Asset-light Asset-light State-of-art Strategic M&A third-party contract Contract manufacturing mode
Slide 8: Presence across Value Chain
Presence across Value Chain Procurement Manufacturing Exports Sales & Marketing Complete control over supply- • Third-party contract • Engaged in direct exports • Dedicated sales & marketing chain, procurement done by manufacturing under own brands & product team for branded sales Trident Lifeline i
Slide 9: Strengthening Presence Across Value Chain
Strengthening Presence Across Value Chain Strategic Acquisition of TNS Pharma Private Limited Upcoming Manufacturing Capacity at TNS Tablets: 6 Crore Monthly 51% Total Equity Stake Acquired Q1FY24 Expected Date of Commissioning Manufacturing Facility Capsules: Dry Powder: Sachin GIDC Classified as a
Slide 10: Expansive Product Portfolio
Expansive Product Portfolio
Slide 11: Expansive Product Portfolio
Expansive Product Portfolio The Company’s growing portfolio of products spans over Product categories ▸ Anti Bacterial ▸ Anti Diarrheal ▸ Anti Fungal ▸ Anti Malarial ▸ Anti Diabetic ▸ Dental Cure ▸ Proton Pump Inhibitor ▸ Anti Protozoal Product Categories ▸Anti Histamine 12 ▸Anti Hypertensive drugs
Slide 12: Expansive Product Portfolio (continued)
Expansive Product Portfolio (continued) The Company’s growing portfolio of products spans over Product categories ▸ Capsule ▸ Tablet ▸ Liquid Ointment ▸ Gel ▸ Ice Gel ▸ Mouthwash Product Categories ▸ Paste 12 ▸ Solution ▸ Suspension ▸ Toothpaste Therapeutic Categories 16 ▸ Syrup ▸ Cream 2 PRODUCT PO
Slide 13: Revenue Break-up: Product Categories
Expansive Product Portfolio (continued) Revenue Break-up: Product Categories Tablets are by far the largest product category (In %) accounting for 63% of the revenue 0 6 6 7 Followed by capsules being the second largest 21 9 9 23 3 5 category which accounts for 17% of the revenue. 4 0 Other categori
Slide 14: Growing Global Footprint
Growing Global Footprint
Slide 15: Growing Geographical Footprint
Growing Geographical Footprint Trident Lifeline has a growing geographical footprint and a formidable presence export markets such as African, Latin American, CIS and East Asian Uzbekistan countries. Tajikistan 10 Venezuela Sudan India Myanmar Cambodia Countries where products are registered Ghana N
Slide 16: Geographical Revenue Mix
Geographical Revenue Mix Being an export-oriented The share of exports • Africa is a major export market for the Other key markets for the Company, Trident has been have increased from company Company include constantly increasing the 55% in FY20 to 76% • Followed by increasing share in Asian • Indi
Slide 17: Bolstering Export Growth
Bolstering Export Growth Trident Lifeline has been making Export product registrations are consistent, upfront investments in a painstaking task, involving export product registrations to significant gestation period bolster revenue growth of 1.5 to 3 years. The Company also needs to register Till d
Slide 18: Bolstering Export Growth (continued)
Bolstering Export Growth (continued) Country-wise product bifurcation Ghana, Venezuela, Cambodia (In %) & Kenya combined accounts Ghana 360 Uzbekistan 27 for 60% the total product Venezuela 182 Georgia 18 registered and under registration. Cambodia 178 Kirgystan 17 Kenya 146 Others 73 Peru 117 Kazak
Slide 19: Leadership
Q ‘c LY Yo O xe) O O —I
Slide 20: Board of Directors
Board of Directors Mr. Hardik Jigishkumar Desai Mr. Shravan Harikrishna Patel Mr. Mayurkumar Mansukhbhai Gajera Mr. Hardik Jigishkumar aged 45 years is Mr. Shravan Harikrishna Patel aged 29 Mr. Mayurkumar Mansukhbhai Gajera aged 38 Promoter-Chairman and Executive Director years is Managing Director
Slide 21: Strategy & Investment Rationale
Strategy & Investment Rationale
Slide 22: Strategic Priorities
Strategic Priorities Continuous Expanding investments in intellectual Building sales & Strengthening Expand product product property marketing supply chain portfolio registrations registrations prowess • 300-400 additional • Registering brand’s • Strengthening strategic • Expanding dedicated • Grow
Slide 23: Investment Rationale
Investment Rationale • Trident’s business model reaps • 1067 registrations in pipeline spread backloaded investment Extensive over 25 countries, with many benefits of product Exponential registrations under advance stages registrations product of the approval growth registrations • Current product r
Slide 24: Financials & Management Commentary
Financials & Management Commentary
Slide 25: Quarterly Profit & Loss Snapshot
Quarterly Profit & Loss Snapshot (₹ in Lakh) Particulars Q4FY23 Q3FY23 Q4FY22 YOY Change (%) FY22 FY23 YOY Change (%) +47% YOY Revenue growth in FY23 Total Revenue 909.51 980.18 911.92 0% 2,237.14 3285.02 47% Total Operating 650.79 742.93 719.29 -10% 1,905.94 2544.14 33% Expenses EBITDA 258.72 237.2
Slide 26: Annual Profit & Loss Snapshot
Annual Profit & Loss Snapshot (₹ in Lakh) Particulars FY20 FY21 FY22 FY23 Total Revenue 505.63 978.12 2,237.14 3285.02 Total Operating Expenses 517.2 836.93 1,905.94 2544.14 EBITDA -11.57 141.2 331.2 740.88 EBITDA (%) -2% 14% 15% 23% Interest Cost 76.21 41.23 12.58 46.59 Depreciation & Amortisation
Slide 27: Management Commentary
Management Commentary • Trident Lifeline has continued to build on its impressive financial performance in Q4FY23, concluding the financial year on a high note. The Company has reported its highest-ever Revenue from Operations, EBITDA, and PAT in FY23, demonstrating significant growth on all key par
Slide 28: Balance Sheet Snapshot
Balance Sheet Snapshot (₹ in Lakh) Particulars FY20 FY21 FY22 FY23 Shareholders Fund -500.31 -217.21 477.57 4563.49 Non Current Liability 646.93 457.65 148.94 226.08 Current Liabilities 286.65 735.61 756.98 1094.90 Other Current Liabilities 103.24 333.81 234.10 613.82 Trade Payable 183.41 401.8 522.
Slide 29: Cash Flow Snapshot
Cash Flow Snapshot (₹ in Lakh) Particulars FY20 FY21 FY22 FY23 Cash from Operating Activities -81.86 -32.02 -21.47 -1744.38 Cash from Investing Activities -13.63 24.79 -44.52 -693.97 Cash from Financing Activities 103.75 1.43 80.19 3799.99 Net Cash Flow 8.26 -5.8 14.20 1361.65 Net Cash at Beginning
Slide 30: Safe Harbour
Safe No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of